Latest papers

Rigorous new approach to constructing a gold standard for validating new diagnostic criteria, as exemplified by the eosinophilia-myalgia syndrome.

Red eye syndrome: clinical and experimental experience in a new aspect of diffuse eosinophilic infiltration?

The toxic oil syndrome: 20 years on.

[Eosinophilic myositis in a 9 year old boy].

Autoimmune diseases associated with drugs, chemicals and environmental factors.

Eosinophilic cholecystitis as a possible late manifestation of the eosinophilia-myalgia syndrome.

Presence of peak X and related compounds: the reported contaminant in case related 5-hydroxy-L-tryptophan associated with eosinophilia-myalgia syndrome.

Over-the-counter melatonin products and contamination.

Aspects of melatonin manufacturing and requirements for a reliable active component.

Synthesis, formation, and occurrence of contaminants in biotechnologically manufactured L-tryptophan.

Eosinophilia-myalgia syndrome case-associated contaminants in commercially available 5-hydroxytryptophan.

Is there any relationship between eosinophilia myalgia syndrome (EMS) and fibromyalgia syndrome (FMS)? An analysis of clinical and immunological data.

Eosinophilia-myalgia syndrome and giant cell myocarditis: a case report and therapeutic approach.

[Eosinophilic myalgia syndrome].

Structural characterization of case-associated contaminants peak C and FF in L-tryptophan implicated in eosinophilia-myalgia syndrome.

Synthesis and formation of an EMS correlated contaminant in biotechnologically manufactured L-tryptophan.

L-tryptophan-related eosinophilia-myalgia syndrome possibly associated with a chronic B-lymphocytic leukemia.

Eosinophilic myopathic syndromes.

On-line HPLC-tandem mass spectrometry structural characterization of case-associated contaminants of L-tryptophan implicated with the onset of eosinophilia myalgia syndrome.

Neurologic, MR imaging, and MR spectroscopic findings in eosinophilia myalgia syndrome.